Locations:
Search
Image content: This image is available to view online.
View image online (https://assets.clevelandclinic.org/transform/00ead1f4-b2fa-4060-8525-5f96297505ba/bolwell_650x450_jpg)
bolwell_650x450
A growing body of evidence suggests that prolonged time to treat (TTT) can negatively impact survival for patients with solid tumors. A number of complicated factors contribute to prolonged TTT; the average even in our nation’s best academic cancer centers is 44 days.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Reducing this number is a daunting but doable task. Two years ago we began to emphasize TTT at Cleveland Clinic. We started with an overall TTT of 40 days, but by committing to multidisciplinary care and integrated practice and emphasizing and measuring TTT, we have achieved 30 days or less in our three largest cancer programs (breast, colorectal and lung).
Read more about how Cleveland Clinic reduced TTT in U.S. News & World Report.
Photo Credit: ©Russell Lee
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients